We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca
News

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca
News

Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca

Credit: Bicycle Therapeutics
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bicycle Therapeutics Expands Strategic Partnership with AstraZeneca"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced that it is expanding its collaboration with AstraZeneca to include additional targets in respiratory and cardio-metabolic diseases.

The original collaboration was signed in late 2016 and with the expansion has a potential value in excess of $1 billion. Under the terms of the collaboration Bicycle is responsible for identifying Bicycles® for an undisclosed number of respiratory, cardiovascular and metabolic disease targets specified by AstraZeneca, while AstraZeneca is responsible for further development and product commercialization. The expansion provides additional disease targets and triggers an undisclosed milestone payment to Bicycle.

“This valuable collaboration increases our ability to explore and deliver on the therapeutic potential of Bicycles outside oncology, our core area of focus,” said Kevin Lee, Chief Executive Officer of Bicycle Therapeutics. “AstraZeneca’s decision to expand our alliance further validates the important work we have achieved together, based on the power and versatility of the Bicycle platform.”

“Our collaboration with Bicycle continues to be highly productive. By expanding our work into new target and indication spaces, we continue to test the platform with the aim of bringing innovative new therapies to patients,” said Menelas Pangalos, Executive Vice President, Innovative Medicines and Early Development Biotech Unit at AstraZeneca.
Advertisement